SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates. 42nd Annual J.P. Morgan Healthcare ConferenceTuesday, January 9th, 2024 […]
Selected a Werner Helicase Inhibitor Development Candidate in collaboration with GSKObserved monotherapy complete responses preclinically in multiple in vivo xenograft MSI-High models and.
IDEAYA Biosciences, Inc. (IDYA) announced selection of a Werner Helicase Inhibitor Development Candidate, a potent, selective, small molecule inhibitor of the helicase domain of Werner protein.